Table 4 Medication exposure from the time of drug initiation to the end of study period

Type of biologic exposure

No. of patients

[N = 32 (%)]

Overall

cumulative dose (grams) [median, range]

Cumulative dose/body weight (mg/kg) [median, range]

# of doses [median, range]

Length of exposure since diagnosis in days

[median, range]

Abatacept

4 (12.5)

15.3 (3.6–26.2)

231.6 (108–375)

21 (8–28)

540.5 (169–732)

Adalimumab

1 (3.1)

480

10.2

12

159

Belimumab

3 (9.3)

3.9 (1–5.3)

75.5 (18.7–78.1)

8 (2–8)

176 (16–235)

Infliximab

2 (6.25)

4.7

91.8

11.5

299

Rituximab

29 (90.6)

5.0 (1.8–9.9)

89.1 (18–192.1)

8 (2–12)

503 (96-12,226)

Tocilizumab

2 (6.25)

3.4

57.9

8

196.5

Ivig (g/kg)

12 (37.5)

263.5 (1–14,193)

6.85 (1–39.8)

11.5 (1–47)

241.5 (1-1462)

Ever received Non-biologics

No. Of patients [N = 32 (%)]

Overall cumulative dose (grams) [median, range]

Cumulative dose/body weight (mg/kg) [median, range]

# of doses [median, range]

Length of exposure since diagnosis in days

[median, range]

Azathioprine

2

37.7

790.6

N/A

496

Cyclophosphamide

15 (46.8)

7.1 (4.3–12.7)

94.6 (40.3–295)

6

148 (84-1152)

Hydroxy-chloroquine

25 (78.1)

N/A

N/A

N/A

536 (72–2801)

Methotrexate

4 (12.5)

1.2 (0.5–2.3)

20.3 (11.9–42.7)

N/A

354 (224–1167)

Mycophenolate

28 (87.5)

1109 (128–6751)

23,680

(1950–400,720)

N/A

921.5

(38-2261)

Prednisone

30 (93.7)

6.1 (0.1–25.4)

95.35 (2.3–542.4)

N/A

525.5 (5-3987)

Solu-medrol

32 (100)

10.4 (3–60)

158.9 (41–1272)

16 (3–60)

547.5 (1-1788)